Baxter to end Alzheimer's trial of Gammagard

05/8/2013 | Yahoo

Baxter International said it is stopping Phase III Alzheimer's disease trials of Gammagard after the intravenous immunoglobulin failed to enhance mental decline and functional ability in patients. Gammagard, also known as intravenous immunoglobulin, is the only Alzheimer's treatment currently in Phase III development. The firm said it will reevaluate its Alzheimer's program and make a decision after analyzing the trial's full results.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA